Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Prospective, Double-blind, Randomized, Placebo-Controlled Phase III Study Evaluating Efficacy and Safety of Octagam 10% in Patients With Dermatomyositis ("ProDERM Study")

NCT02728752 is registered in ClinicalTrials.gov with Octapharma as lead sponsor.

NCT NCT02728752
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02728752 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Prospective, Double-blind, Randomized, Placebo-Controlled Phase III Study Evaluating Efficacy and Safety of Octagam 10% in Patients With Dermatomyositis ("ProDERM Study")
Lead sponsor
Octapharma
Phase
Phase 3
Overall status
Completed
Start date
February 27, 2017
Completion date
November 5, 2019
Enrollment
95 (actual)
Sites
37

Conditions

As the registry lists them; a condition with its own page is linked.

dermatomyositis